BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31835809)

  • 1. Acid Sphingomyelinase Deficiency Ameliorates Farber Disease.
    Beckmann N; Becker KA; Kadow S; Schumacher F; Kramer M; Kühn C; Schulz-Schaeffer WJ; Edwards MJ; Kleuser B; Gulbins E; Carpinteiro A
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathological manifestations of Farber disease in a new mouse model.
    Beckmann N; Kadow S; Schumacher F; Göthert JR; Kesper S; Draeger A; Schulz-Schaeffer WJ; Wang J; Becker JU; Kramer M; Kühn C; Kleuser B; Becker KA; Gulbins E; Carpinteiro A
    Biol Chem; 2018 Sep; 399(10):1183-1202. PubMed ID: 29908121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a Novel Acid Sphingomyelinase Activity Associated with Recombinant Human Acid Ceramidase.
    He X; Schuchman EH
    Biomolecules; 2023 Nov; 13(11):. PubMed ID: 38002305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease.
    Ramsubir S; Nonaka T; Girbés CB; Carpentier S; Levade T; Medin JA
    Mol Genet Metab; 2008 Nov; 95(3):133-41. PubMed ID: 18805722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurodegenerative course in ceramidase deficiency (Farber disease) correlates with the residual lysosomal ceramide turnover in cultured living patient cells.
    Levade T; Moser HW; Fensom AH; Harzer K; Moser AB; Salvayre R
    J Neurol Sci; 1995 Dec; 134(1-2):108-14. PubMed ID: 8747852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of CC ligand 5/RANTES by acid sphingomyelinase and acid ceramidase.
    Jenkins RW; Clarke CJ; Canals D; Snider AJ; Gault CR; Heffernan-Stroud L; Wu BX; Simbari F; Roddy P; Kitatani K; Obeid LM; Hannun YA
    J Biol Chem; 2011 Apr; 286(15):13292-303. PubMed ID: 21335555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulfatide and sphingomyelin loading of living cells as tools for the study of ceramide turnover by lysosomal ceramidase--implications for the diagnosis of Farber disease.
    Levade T; Tempesta MC; Moser HW; Fensom AH; Harzer K; Moser AB; Salvayre R
    Biochem Mol Med; 1995 Apr; 54(2):117-25. PubMed ID: 8581356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Staphylococcus aureus α-Toxin Induces Inflammatory Cytokines via Lysosomal Acid Sphingomyelinase and Ceramides.
    Ma J; Gulbins E; Edwards MJ; Caldwell CC; Fraunholz M; Becker KA
    Cell Physiol Biochem; 2017; 43(6):2170-2184. PubMed ID: 29069651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acid Ceramidase Deficiency in Mice Leads to Severe Ocular Pathology and Visual Impairment.
    Yu FPS; Sajdak BS; Sikora J; Salmon AE; Nagree MS; Gurka J; Kassem IS; Lipinski DM; Carroll J; Medin JA
    Am J Pathol; 2019 Feb; 189(2):320-338. PubMed ID: 30472209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy.
    Dworski S; Lu P; Khan A; Maranda B; Mitchell JJ; Parini R; Di Rocco M; Hugle B; Yoshimitsu M; Magnusson B; Makay B; Arslan N; Guelbert N; Ehlert K; Jarisch A; Gardner-Medwin J; Dagher R; Terreri MT; Lorenco CM; Barillas-Arias L; Tanpaiboon P; Solyom A; Norris JS; He X; Schuchman EH; Levade T; Medin JA
    Biochim Biophys Acta Mol Basis Dis; 2017 Feb; 1863(2):386-394. PubMed ID: 27915031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. rAAV-mediated over-expression of acid ceramidase prevents retinopathy in a mouse model of Farber lipogranulomatosis.
    Zhang H; Nagree MS; Liu H; Pan X; Medin JA; Lipinski DM
    Gene Ther; 2023 Apr; 30(3-4):297-308. PubMed ID: 35902747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: identification of the first large deletion in ASAH1 gene.
    Alves MQ; Le Trionnaire E; Ribeiro I; Carpentier S; Harzer K; Levade T; Ribeiro MG
    Mol Genet Metab; 2013 Jul; 109(3):276-81. PubMed ID: 23707712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acid Ceramidase Deficiency in Mice Results in a Broad Range of Central Nervous System Abnormalities.
    Sikora J; Dworski S; Jones EE; Kamani MA; Micsenyi MC; Sawada T; Le Faouder P; Bertrand-Michel J; Dupuy A; Dunn CK; Xuan ICY; Casas J; Fabrias G; Hampson DR; Levade T; Drake RR; Medin JA; Walkley SU
    Am J Pathol; 2017 Apr; 187(4):864-883. PubMed ID: 28342444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological Inhibition of Acid Sphingomyelinase Ameliorates Experimental Autoimmune Encephalomyelitis.
    Walter S; Gulbins E; Halmer R; Jahromi NH; Becker KA; Schottek A; Blatti C; Davies L; Schnoeder L; Bertsch T; Engelhardt B; Fassbender K
    Neurosignals; 2019; 27(S1):20-31. PubMed ID: 31778303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ceramide accumulation is associated with increased apoptotic cell death in cultured fibroblasts of sphingolipid activator protein-deficient mouse but not in fibroblasts of patients with Farber disease.
    Tohyama J; Oya Y; Ezoe T; Vanier MT; Nakayasu H; Fujita N; Suzuki K
    J Inherit Metab Dis; 1999 Jun; 22(5):649-62. PubMed ID: 10399097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic ceramide accumulation leads to severe and varied pathological consequences.
    Alayoubi AM; Wang JC; Au BC; Carpentier S; Garcia V; Dworski S; El-Ghamrasni S; Kirouac KN; Exertier MJ; Xiong ZJ; Privé GG; Simonaro CM; Casas J; Fabrias G; Schuchman EH; Turner PV; Hakem R; Levade T; Medin JA
    EMBO Mol Med; 2013 Jun; 5(6):827-42. PubMed ID: 23681708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adiponectin overexpression improves metabolic abnormalities caused by acid ceramidase deficiency but does not prolong lifespan in a mouse model of Farber Disease.
    Norris MK; Tippetts TS; Wilkerson JL; Nicholson RJ; Maschek JA; Levade T; Medin JA; Summers SA; Holland WL
    Mol Genet Metab Rep; 2024 Jun; 39():101077. PubMed ID: 38595987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acid Ceramidase Depletion Impairs Neuronal Survival and Induces Morphological Defects in Neurites Associated with Altered Gene Transcription and Sphingolipid Content.
    Kyriakou K; Lederer CW; Kleanthous M; Drousiotou A; Malekkou A
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acid sphingomyelinase deficiency enhances myelin repair after acute and chronic demyelination.
    Chami M; Halmer R; Schnoeder L; Anne Becker K; Meier C; Fassbender K; Gulbins E; Walter S
    PLoS One; 2017; 12(6):e0178622. PubMed ID: 28582448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acid ceramidase and the treatment of ceramide diseases: The expanding role of enzyme replacement therapy.
    Schuchman EH
    Biochim Biophys Acta; 2016 Sep; 1862(9):1459-71. PubMed ID: 27155573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.